Company: CMND
Filing Date: 2025-09-15
Form Type: POS AM
Source: 0001213900-25-087398
Chunk: 19

Company: Clearmind Medicine Inc.
Filing Date: 2025-09-15
Form: POS AM
Chunk 19
---
 ability of our future product candidates to address    
 needs not currently addressed by the psychedelic industry; |

| ● | the ability of our future product candidates to address    
 needs not currently addressed by the psychedelic industry; |

| ● | our ability to obtain and maintain regulatory approval 
 of our future product candidates;                      |

| ● | our plans relating to the further development of our                                         
 future product candidates, including additional disease states or indications we may pursue; |

| ● | existing regulations and regulatory developments in 
 the United States and other jurisdictions;          |

| ● | our plans and ability to obtain or protect intellectual                                                                             
 property rights, including extensions of patent terms where available and our ability to avoid infringing the intellectual property 
 rights of others;                                                                                                                   |

| ● | the ability of our management team to oversee our drug 
 research programs;                                     |

| ● | the need to hire additional personnel and our ability 
 to attract and retain such personnel;                 |

| ● | our estimates regarding expenses, future revenue, capital 
 requirements and needs for additional financing;          |

| ● | our dependence on third parties; |

| ● | our ability to compete with other companies who offer                                 
 products that address similar issues that our future product candidates will address; |

| ● | our financial performance; |

| ● | the period over which we estimate                                                                                                     
 our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; |

| ● | our ability to generate revenue and profit margin under      
 our anticipated contracts which is subject to certain risks; |

<div align='center'>7</div>

| ● | difficulties in our partners’ ability to recruit                                                                                
 and retain qualified physicians and other healthcare professionals, and enforce our non-compete agreements with our physicians; |

| ● | our ability to restructure our operations to comply 
 with future changes in government regulation;       |

| ● | security, political and economic instability in the                                              
 Middle East that could harm our business, including due to the security situation in Israel; and |

| ● | those factors referred to in our 2024 Annual Report                                                            
 incorporated by reference herein in “Item 3. Key Information – D. Risk Factors,” “Item 4. Information on       
 the Company,” and “Item 5. Operating and Financial Review and Prospects,” as well as in our 2024 Annual Report 
 generally, which is incorporated by reference into this prospectus.                                            |

Forward-looking statements are based on our management’s
current expectations,